PNCK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL23113274	0.84	2/20
SCHEMBL23113276	0.84	2/20
SCHEMBL23113699	0.75	2/20
SCHEMBL23113700	0.75	2/20
SCHEMBL23113321	0.68	2/20
SCHEMBL23113323	0.68	2/20
SCHEMBL23113537	0.68	2/20
SCHEMBL23113539	0.68	2/20
SCHEMBL23113449	0.67	2/20
SCHEMBL23113451	0.67	2/20
SCHEMBL28501055	0.58	2/20
SCHEMBL28497274	0.53	2/20
SCHEMBL23113731	0.51	2/20
SCHEMBL23113732	0.51	2/20
SCHEMBL28504770	0.50	2/20
SCHEMBL28504772	0.50	2/20
SCHEMBL28501075	0.47	2/20
SCHEMBL28501078	0.47	2/20
SCHEMBL28504858	0.47	2/20
SCHEMBL28504859	0.47	2/20

Clinical trials — most relevant to PNCK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
COMS for Chronic Ulcers Treatment	PHASE4	RECRUITING
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Cardiac REperfusion With Intralipid® at Reperfusion	PHASE2/PHASE3	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A	EARLY_PHASE1	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia	nan	RECRUITING
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PNCK binder may also engage these)

Protein	Name	Similarity
Q9QYK9	—	1.000	Q9QYK9 →
O70150	—	1.000	O70150 →
CAMK1	Calcium/calmodulin-dependent protein kinase type 1	0.994	landscape →
Q91YS8	—	0.994	Q91YS8 →
Q63450	—	0.993	Q63450 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.992	landscape →
Q9TXJ0	—	0.992	Q9TXJ0 →
CAMK1D	Calcium/calmodulin-dependent protein kinase type 1D	0.992	landscape →
Q6PFQ0	—	0.990	Q6PFQ0 →
Q9SZM3	—	0.990	Q9SZM3 →
Q869W6	—	0.990	Q869W6 →
Q9FMP5	—	0.990	Q9FMP5 →
P10665	—	0.989	P10665 →
Q63531	—	0.989	Q63531 →
AURKC	Aurora kinase C	0.988	landscape →
RPS6KA2	Ribosomal protein S6 kinase alpha-2	0.988	landscape →
A8X6H4	—	0.988	A8X6H4 →
A2ZVI7	—	0.988	A2ZVI7 →
Q2QX45	—	0.988	Q2QX45 →
Q3E9C0	—	0.988	Q3E9C0 →
P28583	—	0.988	P28583 →
Q38869	—	0.987	Q38869 →
Q9M101	—	0.987	Q9M101 →
Q852N6	—	0.987	Q852N6 →
Q42396	—	0.987	Q42396 →
Q5VQQ5	—	0.987	Q5VQQ5 →
Q6Z2M9	—	0.986	Q6Z2M9 →
Q8VDF3	—	0.986	Q8VDF3 →
DAPK2	Death-associated protein kinase 2	0.986	landscape →
Q8BW96	—	0.986	Q8BW96 →